Latest news with #Use
Yahoo
4 days ago
- Business
- Yahoo
EXCLUSIVE: Intelligent Bio's Fingerprint Drug Testing Gains Momentum With New Australian Rollout
Intelligent Bio Solutions Inc. (NASDAQ:INBS) on Wednesday announced that Managed Waste Service plans to implement INBS' Intelligent Fingerprinting Drug Screening System across its New South Wales operations, including its land clearing and green waste processing sites. Managed Waste Service is an Australia-based waste management provider. The decision marks Managed Waste Service's first move into in-house drug testing across multiple locations. More than 20 sites are engaged in remote testing operations. Managed Waste Service plans to conduct pre-employment, random, and for-cause testing on-site, giving operational teams complete control over safety processes without the disruption associated with traditional outsourced Intelligent Fingerprinting Drug Screening System offers a quick, noninvasive method of screening for recent drug use through fingerprint sweat analysis, delivering results in under ten minutes. Intelligent Bio Solutions' technology enables Managed Waste Service to implement a scalable, portable solution that aligns with the nature of their fieldwork, whether testing at a remote clearing site or managing compliance across several waste facilities simultaneously. This implementation reflects Intelligent Bio Solutions' continued expansion into safety-critical industries, with environmental services now joining a growing portfolio of sectors adopting sweat-based drug testing. Intelligent Bio Solutions provides drug testing. Over 450 organizations in 24 countries use its technology to streamline and simplify workplace testing. In June, SMARTOX, a U.S.-based provider of drug and alcohol testing products and services, said it deployed over 50 Intelligent Fingerprinting Drug Screening Readers and facilitated over 7,000 screening tests, including over 1,500 tests in 2024 alone. As adoption grows in the U.S. Forensic Use Only market, Intelligent Bio continues to actively pursue FDA clearance for its opiate test system for codeine. This effort aims to enable expansion into broader U.S. markets this year, including workplace drug testing, using its innovative fingerprint sweat-based testing technology. Price Action: INBS stock is up 1.55% at $1.96 during the premarket session at the last check on Wednesday. Read Next:Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article EXCLUSIVE: Intelligent Bio's Fingerprint Drug Testing Gains Momentum With New Australian Rollout originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Yahoo
11-06-2025
- Business
- Yahoo
Intelligent Bio Solutions Expands U.S. Forensic Market Presence, Seeks FDA Clearance for Breakthrough Fingerprint Drug Testing
SMARTOX has deployed over 50 of INBS' Intelligent Fingerprinting Drug Screening Readers and facilitated over 7,000 screening tests, including more than 1,500 tests in 2024 alone Company continues to actively pursue FDA clearance in connection with planned expansion into broader U.S. markets in 2025 NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced an update on its growing footprint in the U.S. Forensic Use Only Market through its strategic partnership with SMARTOX, a Texas-based leader in drug and alcohol screening services. SMARTOX supports clients across corrections, drug courts, rehabilitation centres, and other forensic environments. It has deployed over 50 Intelligent Fingerprinting Drug Screening Readers and facilitated over 7,000 screening tests, including more than 1,500 tests in 2024 alone, highlighting accelerated demand for non-invasive, rapid testing in forensic settings. INBS' drug screening technology is credited with reducing reliance on invasive methods such as urine or saliva collection, while delivering rapid and reliable results directly linked to the individual tested. As adoption grows in the U.S. Forensic Use Only market, INBS continues to actively pursue FDA clearance for its opiate test system for codeine. This effort aims to enable expansion into broader U.S. markets this year, including workplace drug testing, using its innovative fingerprint sweat-based testing technology. "We have partnered with SMARTOX to expand access to our fingerprint drug screening system across key forensic settings such as criminal justice," said Doug Heath, Vice President of Global Sales at Intelligent Bio Solutions. "SMARTOX's commitment to innovation aligns with our mission to transform drug testing through intelligent, non-invasive technologies." SMARTOX is known for its expertise, innovation, and customer-focused approach to drug testing. Its portfolio includes DOT compliance solutions, instant and lab-based testing, and advanced technologies, including INBS' Intelligent Fingerprinting Drug Screening System, which enables hygienic, non-invasive drug screening in under ten minutes using fingerprint sweat. In addition to serving clients across the U.S., SMARTOX reaches international markets through its distribution network, including Europe, Latin America, New Zealand, and Australia. "Our clients consistently report that the Intelligent Fingerprinting Drug Screening System improves efficiency, enhances user dignity, and simplifies operations," said Duffy Nabors, Vice President of Sales and Marketing at SMARTOX. "They value its speed, ease of use, and non-invasiveness, along with the ability to eliminate gender-specific staff requirements and special facilities. These benefits help our clients reduce turnaround times, lower costs, and eliminate logistical complexities, improving the overall testing experience." About SMARTOX SMARTOX, founded in 2012, is a U.S.-based provider of drug and alcohol testing products and services. It offers a comprehensive portfolio supporting a wide range of settings, including healthcare, justice, corporate, and education. SMARTOX is committed to delivering advanced technology and exceptional results, providing fully integrated services encompassing design, customer service, and administrative support for its product line. The company's footprint spans the U.S. and international markets. SMARTOX is actively scaling its presence in forensic testing markets through new investments, pilot programs, and expanded jurisdictional coverage. About Intelligent Bio Solutions Inc. Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company's current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners. For more information, visit: Forward-Looking Statements: Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.'s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions' public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Company Contact: Intelligent Bio Solutions Inc. info@ LinkedIn | Twitter Investor & Media Contact: Valter Pinto, Managing Director KCSA Strategic Communications PH: (212) 896-1254 INBS@
New York Post
29-05-2025
- Business
- New York Post
Starbucks announces shock change to its rewards program — here's how to score free drinks
Starbucks announced a major change to its reward system. The coffee giant is making it a little harder to rack up Stars this summer, meaning it may take longer for rewards members to gain enough for a free drink. Starting June 24, the points received for using your own to-go reusable cup are changing, according to an email sent to rewards members. Starbucks is making a change to its rewards system. ManuPadilla – Instead of receiving 25 Bonus Stars for every order placed with your own cup, you'll now receive 'double Stars' for the entire order. 'If you bring in two reusable cups and order two handcrafted beverages in a single order, you will receive double Stars on the entire transaction,' the new Starbucks Rewards Terms of Use reads, per AllRecipes. While it might sound like more — and it might be for some customers — you now have to spend a minimum of $12.50 during your visit to get the 25 stars, as opposed to automatically getting them under the current system. Currently, everyone receives 25 stars regardless of how much they order or how many personal cups are used. The points received for using your own to-go reusable cup at Starbucks are changing. ANGELA WEISS/AFP via Getty Images The update benefits customers who tend to spend more money at Starbucks, as well as customers who bring in more than one reusable cup for their order.
Miami Herald
27-05-2025
- Business
- Miami Herald
Bora Biologics Expands San Diego Facility for 2000L+ Scale Biologics Manufacturing, Boosts CDMO Capacity
SAN DIEGO, CALIFORNIA / ACCESS Newswire / May 27, 2025 / Bora Biologics, a leading contract development and manufacturing organization (CDMO) specializing in biologics manufacturing, announced a major expansion of its U.S. FDA-registered commercial manufacturing facility in San Diego. This expansion will add state-of-the-art upstream and downstream GMP processing capabilities to meet the increasing demand for 2000L scale single-use biologics manufacturing, solidifying Bora Biologics' position as a premier biologics CDMO. The expansion adds 8,075 square feet of state-of-the-art GMP manufacturing space to the San Diego biologics manufacturing facility, comprising a cutting-edge upstream mammalian cell culture hall, harvest suite with two inoculation rooms and in-process testing room, capture suite, and a downstream processing suite. This includes 6,950 square feet of new construction and 1,125 square feet of revisions to the existing GMP space. The expanded facility will feature two 2000L Cytiva XDR bioreactors and seed train, providing Bora Biologics' clients with robust and scalable biologics manufacturing solutions. The upstream hall's design allows for future bioreactor expansion up to 5000L scale. The downstream process suite is engineered to efficiently process up to 5000L modern high-titer cell culture processes, ensuring streamlined purification. Bora Biologics' San Diego facility currently offers a comprehensive range of GMP manufacturing suites, including 50L, 250L and 1000L single-use bioreactors dedicated to mammalian cell culture, and a dedicated microbial GMP suite equipped with a 150L stainless steel fermenter and a 300L single-use fermenter expansion capability. The planned addition of the two 2000L single-use bioreactors in Q1 2026 will significantly enhance Bora Biologics' ability to provide seamless scale-up and commercial manufacturing solutions to its clients. "With this expansion, we will be able to offer our customers 2000L commercial capacity with the ability to purify modern high-titer cell culture processes," said John R. Mosack, General Manager & Vice President, Operations of the San Diego Site at Bora Biologics. "In addition to the two 2000L Cytiva bioreactors we are installing now, we will have the space to grow with our customers and meet their evolving needs." Miguel Carrion, Vice President, Process Development and MS&T at Bora Biologics, added, "With the addition of the new Cytiva trains, we now have the ability to offer customers both Thermo Fisher Scientific Single Use and Cytiva Single Use bioreactor trains, providing greater flexibility and options for their specific manufacturing requirements." cGMPnow, a leading provider of GMP facility design and GxP systems implementation and compliance for the biopharmaceutical industry, is providing process equipment, clean utilities, and automation/controls engineering and commissioning, qualification, and validation expertise for this expansion project. Jeff Gilmore, CEO of cGMPnow, expressed his enthusiasm for the partnership, "We are absolutely thrilled to be partnering with Bora Biologics on this critical expansion, leveraging our expertise in biopharmaceutical engineering and cGMP compliance to deliver a state-of-the-art facility that will enable their clients to reach more patients." Cytiva is supplying the advanced bioreactor technology for the expanded facility. Emphasizing Cytiva's support for Bora Biologics' growth, Jordan Heard, Americas Upstream and Consumable Leader (USA) at Cytiva, stated, "Cytiva is proud to support Bora Biologics in their commitment to innovation and growth. Our XDR bioreactors will provide Bora Biologics with the scalability and flexibility needed to meet the evolving demands of the biologics market." DPR Construction, a unique technical builder, is applying its skills and experience to the construction of the expanded facility. Scott Sass, DPR's San Diego Business Unit Leader, shared his excitement about the project. "DPR is excited to partner with Bora Biologics on this project, bringing our expertise in advanced biomanufacturing facility construction to help them expand their capabilities and serve their clients." This expansion underscores Bora Biologics' dedication to providing its clients with cutting-edge manufacturing capabilities and its commitment to supporting the development and commercialization of life-saving therapies. About Bora Biologics Bora Biologics is a global CDMO offering agile, comprehensive end-to-end solutions for biopharma companies worldwide. With a proven track record of over 100 successful cGMP manufacturing batches, Bora Biologics leverages its state-of-the-art, FDA-registered facility in the U.S. and deep expertise in biologics development and manufacturing - including its own FDA-licensed and Health Canada-approved product - to enhance time and cost efficiencies while ensuring effective pathways to market for its clients. Bora Biologics combines innovative early-phase development and late-stage manufacturing capabilities with the expertise and reputation of Bora Pharmaceuticals for flexible and scalable fill/finish services, including stability testing, and final packaging of clinical and commercial products. About cGMP Now cGMPnow provides turnkey GMP systems, accelerating the delivery of next-generation therapies. Specializing in GMP manufacturing facility design, GxP manufacturing and QC laboratory equipment, GxP computerized systems, commissioning/qualification/validation, and procurement services, cGMPnow utilizes a unique project delivery methodology and owner-focused involvement to bring new products to market faster. With expertise in GMP facility design, construction support, and GxP systems, cGMPnow enables clients to begin production efficiently and effectively, accelerating the delivery of life-changing products. About Cytiva Cytiva is a global biotechnology leader committed to supporting customers in the discovery and commercialization of next-generation therapeutics. As part of Danaher, a global science and technology innovator, Cytiva provides dedicated technical expertise and a comprehensive portfolio of tools, technologies, and services that enable the development, manufacture, and delivery of transformative medicines to patients. About DPR Construction DPR Construction is a forward-thinking, self-performing general contractor and construction manager, specializing in technically complex and sustainable projects across a range of sectors, including advanced technology/mission critical, life sciences, healthcare, and higher education. With a commitment to innovation and a purpose to "Build Great Things," DPR leverages its deep technical expertise and self-perform capabilities to deliver predictable outcomes for its clients. Founded in 1990, DPR serves customers internationally with offices across the globe. press release
Miami Herald
16-05-2025
- Business
- Miami Herald
Applied DNA Reports Second Quarter Fiscal 2025 Financial Results
- Therapeutic DNA Production Services Segment (LineaRx) Revenues Up 44% Y/Y, Contributing to a 6% Increase in Total Revenues - - Intra-Quarter Investor Conference Call and Webcast Scheduled for June 3, 2025, at 4:30 PM ET - STONY BROOK, NY / ACCESS Newswire / May 15, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today reported financial results for its second quarter of fiscal 2025 ended March 31, 2025. The Company's Form 10-Q for its fiscal second quarter can be viewed on the SEC Filings page of its Investor Relations website. To align with the Company's Annual Meeting of Stockholders on May 22 and ensure a comprehensive post-meeting update, the quarterly investor call will be held on June 3, on which management will update investors on the Company's strategic priorities. Management Commentary "Amidst a challenging macro environment with regulatory headwinds and volatile equity markets, we concluded a strategic reset and have emerged more focused, leaner, and positioned to meet biopharma's emergent demand for enzymatic DNA with our LineaRx subsidiary positioned as what we believe to be North America's largest, PCR-based producer of cell-free DNA," stated Dr. James A. Hayward, chairman and CEO of Applied DNA. "Our strategic priority going forward is to elevate the execution of LineaRx and Applied DNA Clinical Labs in a way that drives consistent and recurring revenues to support higher gross margins and build shareholder value. "Looking ahead, we believe industry tailwinds are accelerating," Dr. Hayward concluded. "The biopharma industry is announcing substantial, planned investments in U.S. manufacturing; AI drug design is shortening genetic medicine development timelines, but persistent manufacturing bottlenecks tied to plasmid DNA's technical constraints remain; and limitations regarding the scalability, efficiency, and cost constraints of competing enzymatic DNA technologies we believe offer market opportunities. With initial capital investments for our now operational Site 1 GMP facility complete, we believe our rapid DNA production and domestic sourcing capabilities are key differentiators to drive new customer acquisition." Recent Corporate and Operational Updates Corporate: With the completion of its strategic restructuring, the Company expects quarterly cash burn to begin to decline beginning in the quarter ending June 30, 2025. LineaRx (Therapeutic DNA Production and Services subsidiary): Validated GMP Site 1 manufacturing operations in January with production capabilities sufficient to support anticipated near-term manufacturing needs. Site 1 can support an annual revenue capacity between $10 million and $30 million, contingent on product mix and customers added:A quantity of Research Use Only (RUO)-grade LineaDNA™ IVT templates and associated LineaRNAP™ for a U.S.-based mRNA contract development and manufacturing organization (CDMO).RUO-grade quantities of LineaDNA for in vitro studies to support four animal health vaccine candidates, with one LineaDNA construct proceeding to an in vivo follow-on orders from existing customers, notably:A quantity of RUO-grade LineaDNA IVT templates to an APAC-based CDMO of mRNA vaccines and therapeutics.A quantity of LineaDNA to a U.S.-based CRISPR and mRNA therapeutics large-scale manufacturing and delivery of LineaDNA under supply agreements with global manufacturers of in vitro diagnostics (IVDs).Engagement with a U.S.-based therapeutics developer on a challenging self-amplifying mRNA therapy did not result in a first GMP order, though our dialogue remains active for subsequent completion of a proprietary enzyme and buffer system designed to enhance LinearDNA's performance by boosting yields, lowering costs, and enabling production of longer, more complex DNA sequences, such as sa-mRNA. Large-scale manufacturing of the enzyme and buffer by a U.S.-based CDMO is expected to begin in June to launch in Q4'25, LineaPCR™ is an offering to enable customers to self-manufacture LineaDNA with an easy, end-to-end process to simplify existing multi-week, multi-vendor, PCR-based drug discovery LineaDNA IVT Evaluation Kits - three 25μg templates and associated LineaRNAP aimed at driving adoption of the LineaIVT platform by showcasing its advantages over plasmid-based systems and accelerating customer engagement in mRNA manufacturing. Kits will be offered at industry conferences and on Applied DNA Clinical Labs (MDx Testing Services subsidiary): Submitted a validation package to the New York State Department of Health (NYSDOH) for a PCR-based H5N1 diagnostic as a laboratory-developed test for the detection and subtyping of H5 bird flu, which is currently under review by TR8™ PGx pharmacogenomic sub-panels for indication-specific use, complementing full-panel testing. The sub-panels are designed to lower adoption barriers for institutions, clinicians, and patients. The first sub-panel launched is TR8 PGx for Pre-emptive Oncology Care relating to fluoropyrimidine-based cancer therapeutics. Second Quarter Fiscal 2025 Financial Highlights Total revenues: $983 thousand, compared to $930 thousand for the second quarter of fiscal 2024. Segment information is detailed in the 'Note H - Segment Information' section of the Form 10-Q for the period reported:Therapeutic DNA Production (LineaRx) segment revenues increased 44% compared to the same period of fiscal 2024. The increase in segment revenues was driven by a large shipment to a large-scale DNA manufacturing customer, as well as the timing of shipments for a second large-scale DNA manufacturing Testing Services (Applied DNA Clinical Labs) segment revenues decreased 33% compared to the same period of fiscal 2024 due to a decrease from COVID-19 surveillance loss: $3.5 million, compared to an operating loss of $3.6 million for the second quarter of fiscal loss: $3.3 million, compared to a net loss of $4.5 million for the second quarter of fiscal 2024. The improvement in net loss primarily reflects a loss on the issuance of warrants in the prior period that was not repeated in the reported EBITDA: Negative $3.3 million, compared to negative $3.3 million for the second quarter of fiscal and cash equivalents as of March 31, 2025: $6.8 million, which includes $1.0 million of proceeds from the exercise of Series A warrants. June 3 Intra-Quarter Investor Conference Call Information Management will hold a conference call to review the Company's strategic priorities on June 3, 2025, at 4:30 p.m. Eastern Time. To participate in the conference call, please follow the instructions below. While every attempt will be made to answer investors' questions on the Q&A portion of the call, not all questions may be answered. An accompanying slide presentation will be embedded in the webcast (live and replay) that can also be accessed via the 'Company Presentations' page of the Applied DNA investor relations website. To participate, please ask to be joined to the 'Applied DNA Sciences' call: Domestic callers (toll free): 844-887-9402International callers: 412-317-6798Canadian callers (toll free): 866-605-3852Live and replay of webcast: link Telephonic replay (available 1 hour following the conclusion of the live call through June 10, 2025): Domestic callers (toll free): 1-877-344-7529Canadian callers (toll free): 1-855-669-9658Replay access code: 3446494 Information about Non-GAAP Financial Measures As used herein, "GAAP" refers to accounting principles generally accepted in the United States of America. To supplement our condensed consolidated financial statements prepared and presented in accordance with GAAP, this earnings release includes Adjusted EBITDA, which is a non-GAAP financial measure as defined in Rule 101 of Regulation G promulgated by the Securities and Exchange Commission. Generally, a non-GAAP financial measure is a numerical measure of a company's historical or future performance, financial position, or cash flows that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. The presentation of this non-GAAP financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information presented in accordance with GAAP. We use this non-GAAP financial measure for internal financial and operational decision-making purposes and as a means to evaluate period-to-period comparisons of the performance and results of operations of our core businesses. Our management believes that these non-GAAP financial measures provide meaningful supplemental information regarding the performance of our businesses by excluding non-cash expenses that may not be indicative of our recurring operating results. We believe this non-GAAP financial measure is useful to investors as they allow for greater transparency with respect to key metrics used by management in its financial and operational decision making. "EBITDA"- is defined as earnings (loss) before interest expense, income tax expense and depreciation and amortization expense. "Adjusted EBITDA"- is defined as EBITDA adjusted to exclude (i) stock-based compensation and (ii) other non-cash expenses and non-cash gains/income. About the LineaDNA™ and Linea IVT™ Platforms The Linea DNA platform is an entirely cell-free DNA production platform founded on Applied DNA's long-standing expertise in the large-scale enzymatic production of DNA. Capable of producing DNA in quantities ranging from milligrams to grams, the Linea DNA platform can produce high-fidelity DNA constructs ranging from 100bp to 20kb in size. The DNA produced via the Linea DNA platform is free of the adventitious DNA sequences found in other sources of DNA, is rapidly scalable, and provides for simple chemical modification of DNA constructs. The Linea IVT platform combines DNA IVT templates manufacturing via the Linea DNA platform with a proprietary Linea™ RNAP to enable mRNA and sa-mRNA manufacturers to produce what Applied DNA believes to be better mRNA faster, with advantages over conventional mRNA production, including: 1) the elimination of plasmid DNA as a starting material; 2) the prevention or reduction of double-stranded DNA (dsRNA) contamination; and 3) simplified mRNA production workflows. About Applied DNA Sciences Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we operate in two business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; and (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services. Visit for more information. Follow us on X and LinkedIn. Join our mailing list. Forward-Looking Statements The statements made by Applied DNA in this press release may be "forward-looking" in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA's future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. These forward-looking statements are based largely on the Company's expectations and projections about future events and future trends affecting our business and are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including statements regarding its goal to position the Company for long-term growth and value creation and the potential to achieve that goal, including the future success of its Linea DNA and Linea IVT platforms. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, unknown future ability to remain compliant with all Nasdaq listing standards, unknown future demand for its biotherapeutics products and services, the unknown amount of revenues and profits that will result from its Linea IVT and/or Linea DNA platforms, the fact that there has never been clinical trial material and/or a commercial drug product produced utilizing the LineaDNA and/or Linea IVT platforms, the unknown amount of revenues and profits that will result from its current and planned future ADCL testing services, whether its restructuring will position the Company for future growth potential, as well as various other factors detailed from time to time in Applied DNA's SEC reports and filings, including its Annual Report on Form 10-K filed on December 17, 2024, Forms 10-Q filed on February 13, 2025 and May 15, 2025, and other reports it files with the SEC, which are available at Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law. Investor Relations contact: Sanjay M. Hurry, 917-733-5573, Web: X: APDN - Financial Tables Follow - APPLIED DNA SCIENCES, CONSOLIDATED BALANCE SHEETS APPLIED DNA SCIENCES, CONSOLIDATED STATEMENTS OF OPERATIONS(unaudited) APPLIED DNA SCIENCES, AND RECONCILIATION OF ADJUSTED EBITDA(unaudited) SOURCE: Applied DNA Sciences, Inc.
